NEULANDLAB · Health Care · 2026-08-21

Neuland Laboratories Ltd

9.0★★★ PrimeStrong +15.3Stage 2 · wk 12In scan: Breakout WatchMARKET: BULL RISING · 2026-08-21
₹23,301
-1.13% today
₹29,895 Cr · Large cap
About this companyHealth Care· Pharmaceuticals
Expand ▾

Neuland Laboratories Limited engages in the manufacture and sale of active pharmaceutical ingredients (APIs) in India, Europe, the United States, and internationally. It also provides custom manufacturing solutions, as well as peptide synthesis services. Neuland Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

Visit company website →
P/E (TTM)
59.2
Forward 36.6
Earnings Growth (YoY)
+664.9%
Revenue +136.4%
Dividend Yield
0.20%
P/B 13.3
vs 52W High
-1.5%
₹11,555 lo₹23,661 hi
Near 52W high
How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.
Stage Maturity
Week 12
1w13w26w
Week 12 — early Stage 2, building
How long this stock has been in Stage 2. The sweet spot is typically 13–26 weeks — enough time to prove the structure holds, not so long it's extended. Very fresh (wk 1–4) often needs more time to confirm.
vs 200 DMA
44.2%
200 DMA: ₹16,160.7 · rising
Long-term trend anchor. When stock and Nifty are both above their 200 DMA, the macro backdrop supports continuation.
Rel Volume
0.41x
vs 50-day avg
Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.
Trend Health
↑
MA20 trending up · +11.3% vs MA50 +10.5%
Two-layer momentum read: the glyph shows whether the 20-day MA is rising (↑/↗), flat (→), or rolling over (↓). The ⇈ flag fires when the 20-day MA is pulling away from the 50-day MA — short-term momentum building on top of the longer trend. Best when both glyphs agree.
Sector
Health Care
↑ Building
Stage 2%
55.5%
20d Δ
+3.9pp
1M return
+2.7%
3M return
+9.6%
Sector Stage-2 % · last 20 days
This stock ranks #11 of 84 Stage 2 stocks in Health Care by RS. Leading the sector.
Industry
Pharmaceuticals
↑ Building
Stage 2%
56.1%
20d Δ
+5.6pp
1M return
+2.7%
3M return
+10.4%
Industry Stage-2 % · last 20 days
Ranks #11 of 58 Stage 2 stocks in this industry. Top tier.
Price + Volume Chart
Loading price chart…
Stage Cycle Timeline2023-05-29 → 2026-08-21
S2 52w
S2 30w
S1 14w
S2 18w
2023-05-292026-08-21
S1S2S3S4Setup score (0–10, dashed line at 5)
S2 52w → S3 4w → S2 30w → S3 11w → S4 8w → S1 14w → S2 18w → S3 6w → S4 9w → S1 5w → S2 12w current
Total tracked: 168 weeks across 11 stage runs.
1M
+26.4%
3M
+39.6%
6M
+75.9%
YTD
+55.8%
1Y
+79.0%
Scan Membership
Breakout Watch
Latest: 2026-06-01
3 appearances in last 60 days. First seen: 2024-06-21.
Stocks that stay in the scan for 13+ weeks are in the highest observed-return cohort — they keep qualifying because the structure remains intact, not by luck. Persistence in the scan is itself a quality signal.
Recent Stage Timeline
2026-08-21S2
Wk 12 · Vol —x
2026-08-20S2
Wk 12 · Vol —x
2026-08-19S2
Wk 12 · Vol —x
2026-08-18S2
Wk 12 · Vol —x
2026-08-17S2
Wk 11 · Vol —x
2026-08-14S2
Wk 11 · Vol —x
2026-08-13S2
Wk 11 · Vol —x
2026-08-12S2
Wk 11 · Vol —x
2026-08-11S2
Wk 11 · Vol —x
2026-08-10S2
Wk 10 · Vol —x
2026-08-07S2
Wk 10 · Vol —x
2026-08-06S2
Wk 10 · Vol —x
Sector Peers — Stage 2All →
ALIVUS
wk 19 · -3.4% from hi
9.0
SAILIFE
wk 25 · -1.0% from hi
8.8
DIVISLAB
wk 14 · -0.0% from hi
8.8
SHILPAMED
wk 15 · -0.9% from hi
8.6
MARKSANS
wk 13 · -3.5% from hi
8.4
Moving averages & range
50 DMA
₹19,624.1
200 DMA
₹16,160.7
52W High
₹23,661
52W Low
₹11,555
5D Low
₹23,290
Resistance levels (recent highs)
20d High
₹23,661
60d High
₹23,661
120d High
₹23,661
250d High
₹23,661
Next resistance
+1.5%
to 20d High

All analytics based on EOD data. Data as of 2026-08-21. Past data patterns are not indicative of future results. This page is a data analytics tool only.